UiPath (NYSE:PATH) Given New $25.00 Price Target at Morgan Stanley

UiPath (NYSE:PATH) had its target price upped by Morgan Stanley from $17.00 to $25.00 in a research note released on Thursday morning, Benzinga reports. Morgan Stanley currently has an equal weight rating on the healthcare company’s stock.

PATH has been the subject of a number of other reports. William Blair assumed coverage on UiPath in a research report on Tuesday, January 2nd. They issued an outperform rating for the company. TD Cowen raised their price objective on UiPath from $25.00 to $28.00 and gave the company an outperform rating in a research report on Thursday. Barclays raised their price objective on UiPath from $23.00 to $25.00 and gave the company an equal weight rating in a research report on Friday. BMO Capital Markets lifted their price target on UiPath from $19.00 to $24.00 and gave the stock a market perform rating in a report on Friday, December 1st. Finally, Royal Bank of Canada lifted their price target on UiPath from $19.00 to $24.00 and gave the stock a sector perform rating in a report on Friday, December 1st. Nine investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of Hold and a consensus target price of $27.13.

UiPath Trading Up 1.4 %

Shares of PATH traded up $0.32 during mid-day trading on Thursday, reaching $23.07. The company’s stock had a trading volume of 9,842,354 shares, compared to its average volume of 10,074,664. UiPath has a 1-year low of $12.38 and a 1-year high of $27.87. The stock has a market cap of $13.06 billion, a P/E ratio of -135.46 and a beta of 0.97. The business has a 50-day simple moving average of $23.52 and a two-hundred day simple moving average of $20.70.

Insider Activity

In other news, CFO Ashim Gupta sold 125,000 shares of UiPath stock in a transaction on Thursday, January 4th. The stock was sold at an average price of $22.59, for a total value of $2,823,750.00. Following the transaction, the chief financial officer now owns 858,148 shares in the company, valued at approximately $19,385,563.32. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In related news, Director Rich Wong sold 200,000 shares of the business’s stock in a transaction on Monday, January 8th. The stock was sold at an average price of $23.12, for a total transaction of $4,624,000.00. Following the sale, the director now owns 429,418 shares in the company, valued at approximately $9,928,144.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Ashim Gupta sold 125,000 shares of the business’s stock in a transaction on Thursday, January 4th. The stock was sold at an average price of $22.59, for a total value of $2,823,750.00. Following the sale, the chief financial officer now owns 858,148 shares in the company, valued at approximately $19,385,563.32. The disclosure for this sale can be found here. In the last quarter, insiders have sold 411,000 shares of company stock worth $9,418,670. Insiders own 31.03% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. lifted its stake in shares of UiPath by 0.9% in the 4th quarter. Vanguard Group Inc. now owns 38,084,858 shares of the healthcare company’s stock valued at $946,028,000 after purchasing an additional 334,085 shares during the period. Gerber LLC acquired a new position in shares of UiPath in the 4th quarter valued at about $455,000. Sierra Summit Advisors LLC acquired a new position in UiPath during the 4th quarter worth approximately $5,897,000. GSA Capital Partners LLP acquired a new position in UiPath during the 4th quarter worth approximately $259,000. Finally, Public Employees Retirement System of Ohio raised its stake in UiPath by 4.1% during the 4th quarter. Public Employees Retirement System of Ohio now owns 159,357 shares of the healthcare company’s stock worth $3,958,000 after buying an additional 6,335 shares during the period. 59.04% of the stock is owned by institutional investors and hedge funds.

UiPath Company Profile

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, and Japan. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.